tbuckley/cabot-search huggingface dataset:
A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma
Authors: Emily Bryer, Alexander Dew, Elizabeth Hill, Elizabeth Gil Ramirez, Candis Morrison, Ashley Carpenter, Monica Epstein, Michael Emanuel, Kevin Camphausen, Jennifer Jones, Dickran Kazandjian
Journal: Blood (2020)
Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study
Authors: Lori S. Muffly, Vandana Sundaram, Connie Chen, Ilana Yurkiewicz, Eric Kuo, Sarah Burnash, Jay Y. Spiegel, Kelly Chyan, Sally Arai, Matthew J. Frank, Laura J. Johnston, Robert Lowsky, Everett H Meyer, Robert S. Negrin, Andrew R. Rezvani, Surbhi Sidana, Parveen Shiraz, Judith A Shizuru, Wen-Kai Weng, Michaela Liedtke, Hyma T. Vempaty, David B. Miklos
Journal: Blood (2020)
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Authors: Yun Fan, Jun Zhao, Qiming Wang, Dingzhi Huang, Xingya Li, Jianhua Chen, Yong Fang, Jianchun Duan, Caicun Zhou, Yanping Hu, Haihua Yang, Yi Hu, Jianying Zhou, Xiaoyan Lin, Lifeng Wang, Zhijie Wang, Yanjun Xu, Tao Zhang, Wei Shi, Jianjun Zou, Jie Wang
Journal: Journal of Thoracic Oncology (2020)
Abstract 17401: Ranolazine: A Novel Anti-ischemic Drug in Preventing Post-operative Af in Patients Undergoing Coronary Artery Bypasses Grafting: Meta-analysis
Authors: Chintan Trivedi, Luigi Di Biase, Sanghamitra Mohanty, Carola Gianni, Mahmut Gunes, Yalçin Gökoglan, Andrea Natale
Journal: Circulation (2015)

Introduction: Atrial fibrillation (AF) is common after coronary artery bypass grafting (CABG). Ranolazine is a novel drug used in the treatment of angina, which also has antiarrhythmic properties. Recent studies demonstrated the benefit of ranolazine in preventing post-operative AF (POAF) in patients undergoing CABG. Hypothesis: To assess the role of ranolazine in preventing POAF in patients undergoing CABG surgery. Methods: We performed comprehensive search of PubMed, MEDLINE, and Cochrane library database on the study assessing the effectiveness of ranolazine in preventing POAF by comparing it with standard therapy. Meta-analysis was performed by fixed effect model by entering POAF events and the total population from each study. Data are expressed as Odds ratio (OR) with 95% confidence interval (CI). Results: A total of three studies with 628 patients (259 pts in ranolazine group, 369 pts in standard therapy group) were included in the meta-analysis. In pooled analysis, ranolazine was associated with 54% reduction in post-operative AF events compared to standard therapy [odds ratio = 0.46 (0.31, 0.70), P&lt;0.001]. The number needed to be treated was 7.14. In one of the study, more patients in ranolazine group (52.2%) had symptomatic hypotension three days after the surgery. Conclusions: Ranolazine may prove beneficial in the prevention of POAF following CABG. However, because of small number of studies further research with large randomized clinical trial is warranted to determine specific dose and duration of ranolazine therapy.
Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature
Authors: Abdul Hamid Bazarbachi, Herve Avet-Loiseau, Zachary R Hunter, Raphael Szalat, Anil Aktas-Samur, Masood A. Shammas, Jill Corre, Mariateresa Fulciniti, Kenneth Anderson, Giovanni Parmigiani, Steven Treon, Mohamad Mohty, Mehmet K. Samur, Nikhil C. Munshi
Journal: Blood (2020)
An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib
Authors: John Mascarenhas, Alessandro M. Vannucchi, Adam J. Mead, Regina Garcia-Delgado, Andrzej Pluta, Hope Qamoos, Anne Uyei, Damaj Gandhi Laurent, Haifa K Al-Ali
Journal: Blood (2020)
Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT)
Authors: Hind Alotaibi, Mahmoud Aljurf, Regis Peffault De Latour, Shahid Iqbal, Andrea Bacigalupo, Judith Marsh, Hubert Schrezenmeier, Eliane Gluckman, Mansour Alfayez, Britta Hoechsmann, Constantijn Halkes, Josu de la Fuente, Nawal AlShehry, Simone Cesaro, Jakob Passweg, Carlo Dufour, Antonio Risitano, John F. DiPersio, Ibraheem Motabi
Journal: Blood (2020)
Abstract 461: Use of Cardiac Magnetic Resonance Imaging for the Early Detection of Programmed Cell Death-1 Blockade-induced Cardiotoxicity in a Mouse Model
Authors: Shirley Xu, Badri Karthikeyan, Min Chen, Swati D Sonkawade, Joseph Spernyak, Steven Turowski, Umesh C Sharma, Saraswati Pokharel
Journal: Circulation Research (2020)

Introduction: Immunotherapy has revolutionized the treatment of advanced stage lung cancers and melanoma. However, serious cardiotoxic side effects such as acute myocarditis, heart block, and sudden cardiac arrest have been reported. There is an urgent need to develop accurate diagnostic modalities for the early detection of this condition, such that toxic therapies can be adjudicated based on the anticipated risks vs. benefits. Hypothesis: Programmed cell death-1 (PD-1) blockade-induced cardiotoxicity, presenting as myocarditis or contractile dysfunction, can be detected at an early stage by cardiac magnetic resonance imaging (MRI). Methods: To develop a murine model of PD-1 blockade-induced cardiotoxicity, we intraperitoneally administered 200 μg (10 mg/kg) of PD-1 antibody (Ab) or IgG isotype control every 3 days for a total of 14 doses. Cardiac function was monitored by MRI with gadolinium infusion. Serum was collected at 27 days and at the time of sacrifice. Immunohistochemical stains were performed on formalin-fixed paraffin embedded tissues. Results: Blockade in mice trended towards reduced myocardial signal intensity (SI) after the gadolinium injection, one month after the last dose of PD-1 antibody (myocardial SI: control 2.55 ± 0.168, PD-1 Ab 2.02 ± 0.164, p=0.063, n=4-7). Three months after the last injection, late gadolinium myocardial SI was significantly reduced in treated mice (myocardial SI: control 2.84 ± 0.352, PD-1 Ab 1.50 ± 0.308, p=0.024, n=4-5). There were also significant decreases in stroke volume (mL: control 10.4 ± 0.355, PD-1 Ab 8.36 ± 0.599, p=0.030, n=4-5), radial strain (%: control 49.9 ± 3.91, PD-1 Ab 33.5 ± 3.00, p=0.012, n=4-5), peak acceleration (cm/s 2 : control 7.24 ± 1.03, PD-1 Ab 3.51 ± 1.08, p=0.044, n=4-5), and peak deceleration (cm/s 2 : control -8.03 ± 0.78, PD-1 Ab -4.64 ± 1.04, p=0.042, n=4-5) times. Interestingly, a subset of animals also had serum antibodies directed against cardiac troponin I peptide sequence. Conclusions: Our study showed that cardiac MRI with gadolinium can identify abnormal myocardial perfusion and reduced contractile function in mice treated with a PD-1 blocker. The presence of serum antibodies against cardiac troponin I may have a mechanistic value, which warrants further investigation.
VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Authors: Michael Wang, Jacqueline C. Barrientos, Richard R. Furman, Matthew Mei, Paul M. Barr, Michael Y. Choi, Sven de Vos, Avyakta Kallam, Krish Patel, Simon Rule, Kate Flanders, Katti A. Jessen, Peter C. Riebling, Patricia Graham, Lydia King, Elizabeth M. Schmidt, Brian J. Lannutti, David M. Johnson, Langdon L. Miller, Stephen E. Spurgeon
Journal: Blood (2020)
Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study
Authors: Cristina De Ramón, Jose Angel Hernandez-Rivas, Jose Antonio Rodríguez García, Enrique M. Ocio, María Teresa Gómez-Casares, Javier López Jiménez, Carlos Solano, Joaquín Martínez-López, Anna Sureda, Manuel Jurado, Raul Córdoba, Celina Benavente, Pascual Marco, Jose Antonio Pérez-Simón, Jose Maria Moraleda, Angela Figuera, Emilia Pardal, Cristina Pascual Izquierdo, Ramon Garcia-Sanz
Journal: Blood (2020)
Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA
Authors: Maxime Taquet, Sierra Luciano, John R Geddes, Paul J Harrison
Journal: The Lancet Psychiatry (2020)

Adverse mental health consequences of COVID-19, including anxiety and depression, have been widely predicted but not yet accurately measured. There are a range of physical health risk factors for COVID-19, but it is not known if there are also psychiatric risk factors. In this electronic health record network cohort study using data from 69 million individuals, 62 354 of whom had a diagnosis of COVID-19, we assessed whether a diagnosis of COVID-19 (compared with other health events) was associated with increased rates of subsequent psychiatric diagnoses, and whether patients with a history of psychiatric illness are at a higher risk of being diagnosed with COVID-19.We used the TriNetX Analytics Network, a global federated network that captures anonymised data from electronic health records in 54 health-care organisations in the USA, totalling 69·8 million patients. TriNetX included 62 354 patients diagnosed with COVID-19 between Jan 20, and Aug 1, 2020. We created cohorts of patients who had been diagnosed with COVID-19 or a range of other health events. We used propensity score matching to control for confounding by risk factors for COVID-19 and for severity of illness. We measured the incidence of and hazard ratios (HRs) for psychiatric disorders, dementia, and insomnia, during the first 14 to 90 days after a diagnosis of COVID-19.In patients with no previous psychiatric history, a diagnosis of COVID-19 was associated with increased incidence of a first psychiatric diagnosis in the following 14 to 90 days compared with six other health events (HR 2·1, 95% CI 1·8-2·5 vs influenza; 1·7, 1·5-1·9 vs other respiratory tract infections; 1·6, 1·4-1·9 vs skin infection; 1·6, 1·3-1·9 vs cholelithiasis; 2·2, 1·9-2·6 vs urolithiasis, and 2·1, 1·9-2·5 vs fracture of a large bone; all p<0·0001). The HR was greatest for anxiety disorders, insomnia, and dementia. We observed similar findings, although with smaller HRs, when relapses and new diagnoses were measured. The incidence of any psychiatric diagnosis in the 14 to 90 days after COVID-19 diagnosis was 18·1% (95% CI 17·6-18·6), including 5·8% (5·2-6·4) that were a first diagnosis. The incidence of a first diagnosis of dementia in the 14 to 90 days after COVID-19 diagnosis was 1·6% (95% CI 1·2-2·1) in people older than 65 years. A psychiatric diagnosis in the previous year was associated with a higher incidence of COVID-19 diagnosis (relative risk 1·65, 95% CI 1·59-1·71; p<0·0001). This risk was independent of known physical health risk factors for COVID-19, but we cannot exclude possible residual confounding by socioeconomic factors.Survivors of COVID-19 appear to be at increased risk of psychiatric sequelae, and a psychiatric diagnosis might be an independent risk factor for COVID-19. Although preliminary, our findings have implications for clinical services, and prospective cohort studies are warranted.National Institute for Health Research.
3D printed <i>in vitro</i> tumor tissue model of colorectal cancer
Authors: Haoxiang Chen, Yanxiang Cheng, Xiaocheng Wang, Jian Wang, Xuelei Shi, Xinghuan Li, Weihong Tan, Zhikai Tan
Journal: Theranostics (2020)

The tumor microenvironment (TME) determines tumor progression and affects clinical therapy. Its basic components include cancer-associated fibroblasts (CAFs) and tumor-associated endothelial cells (TECs), both of which constitute the tumor matrix and microvascular network. The ability to simulate interactions between cells and extracellular matrix in a TME
Comparison of the gut microbiota of short-term and long-term medical workers and non-medical controls: a cross-sectional analysis
Authors: Ning Zheng, Sheng-Hui Li, Bo Dong, Wen Sun, Huai-Rui Li, Yong-Li Zhang, Peng Li, Zhi-Wei Fang, Chang-Ming Chen, Xiu-Yan Han, Bo Li, Si-Yi Zhang, Miao Xu, Gui-Xin Zhang, Yi Xin, Yu-Fang Ma, Xian-Yao Wan, Qiu-Long Yan
Journal: Clinical Microbiology and Infection (2020)
SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial
Authors: Andrea Massimiliano Tomirotti, Daniela Bellarosa, Scott R. Solomon, Aziz Nazha, Stephen A Strickland, Roland P Walter, Farhad Ravandi, Krzysztof Brzózka, Milena Mazan, Simone Baldini, Massimiliano Salerno, Monica Binaschi, Dirk Laurent, Andrea Pellacani
Journal: Blood (2020)
Audio Interview: A New Monoclonal Antibody for Covid-19
Authors: Eric J. Rubin, Lindsey R. Baden, Stephen Morrissey
Journal: New England Journal of Medicine (2020)

A New Monoclonal Antibody for Covid-19 In this audio interview conducted on October 28, 2020, the editors discuss the fundamentals of antibody therapy and the results of an early-phase trial of a n...
Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up
Authors: Thomas Pincez, Helder Fernandes, Thierry Leblanc, Gérard Michel, Vincent Barlogis, Yves Bertrand, Bénédicte Neven, Wadih Abou Chahla, Marlène Pasquet, Corinne Guitton, Aude Marie-Cardine, Isabelle Pellier, Corinne Armari-Alla, Joy Benadiba, Pascale Blouin, Eric Jeziorski, Frederic Millot, Catherine Paillard, Caroline Thomas, Nathalie Cheikh, Sophie Bayard, Fanny Fouyssac, Christophe Piguet, Mariana Deparis, Claire Briandet, Eric Doré, Judith Landman-Parker, Guy Leverger, Nathalie Aladjidi
Journal: Blood (2020)
Impact of Minimal Residual Disease and Chimerism Monitoring at Different Timepoints after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Authors: Reyes María Martín-Rojas, Gillen Oarbeascoa, Rebeca Bailén, Ignacio Gómez-Centurión, Luis Miguel Juarez, Nieves Dorado, Carolina Martínez-Laperche, Ana Pérez-Corral, Ismael Buño, Javier Anguita, Jose L. Diez-Martin, Mi Kwon
Journal: Blood (2020)
The Genetic Landscape in Elderly DLBCL Aged &amp;gt; 75 Years in the Australasian Leukaemia &amp; Lymphoma Group NHL29 Iric Trial Identifies New Targetable Mutations
Authors: Sewa Rijal, Jun Hee Lim, Lillian Smyth, Caitlin Coombes, Sanjiv Jain, Kartik Saxena, Judith Trotman, Emma Verner, Maher K. Gandhi, Kaushal Gandhi, Dipti Talaulikar
Journal: Blood (2020)
Revisiting child and adolescent health in the context of the Sustainable Development Goals
Authors: Zulfiqar A. Bhutta, Kathryn M. Yount, Quique Bassat, Artur A. Arikainen
Journal: PLoS Medicine (2020)

The year 2020-five years since 189 countries signed the Sustainable Development Goals (SDGs)-has been consumed by the global response to COVID-19.To date, this pandemic has resulted in over 38 million cases and well over a million deaths [1].One collateral effect of COVID-19 has been the setting aside of many SDGs and efforts to track progress towards them.Attention to children during the pandemic has concentrated on school closures, food insecurity, and access to care within health systems taxed by COVID-19 mitigation and response efforts [2].The situation of child and adolescent health before COVID-19, and consequences of the pandemic on specific health targets for SDG 3, therefore deserve attention.As the Millennium Development Goals (MDGs) ended in 2015, activities and plans addressed the global compacts for reducing child mortality.A focus was on determinants, such as maternal and child undernutrition, gender inequities, and intersecting vulnerabilities.Because adolescents were largely ignored in the MDG process, advocacy and effort were invested to make them central to the SDG agenda.The renewed global strategy for Every Woman Every Child, launched by the UN Secretary General in 2013, was a segue to the SDGs and an effort to go beyond survival toward a transformative agenda that included healthy development [3].Advocacy for the integration of health, nutrition, and early child development led to the development of the nurturing care framework [4].As we examine the situation more than 5 years into the SDGs, several concerns emerge.Despite progress, the field remains fragmented, with limited actions in countries to develop integrated strategies for reproductive, maternal, newborn and child health (RMNCH), or inclusion of adolescent health within national plans [5].Work on the drivers of adolescent health, well being, and empowerment is underway but has yet to translate into a reasonable global strategy.This lag stems from complex, multilevel social influences during adolescence [6], insufficient disaggregation of data on adolescents, suboptimal measurement and a lack of well-defined indicators [7-9], and limited evidence on the differential impacts of social policies and programs [8] within adolescence and between adolescence and adulthood.Within health systems, many nutrition programs remain poorly integrated with other RMNCH programs and few have substantive links with sectors outside health.With the unfinished agenda for maternal, newborn and child deaths, rigorous studies to address mechanisms and hitherto unrecognized causes of excess mortality are just beginning to yield results, albeit with older pediatric age groups remaining significantly understudied, even at the simplest descriptive
Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels
Authors: David H. Henry, John Glaspy, Rosemary Anne Harrup, Moshe Mittelman, Amy Zhou, Hetty E. Carraway, Charles Bradley, Gopal Saha, Pamela Bartels, Robert Leong, Peony Yu
Journal: Blood (2020)
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Authors: Anthony R. Mato, John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Ewa Lech-Marańda, Toby A. Eyre, Jennifer A. Woyach, William G. Wierda, Chan Yoon Cheah, Lindsey E Roeker, Manish R. Patel, Bita Fakhri, Minal Barve, Constantine S. Tam, David John Lewis, James N. Gerson, Alvaro J. Alencar, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen J. Schuster, Jessica Chen, Binoj Nair, Donald Tsai, Nora C. Ku, Matthew S. Davids, Jennifer R Brown, Wojciech Jurczak
Journal: Blood (2020)
Comparative Genome Analysis of <i>Scutellaria Baicalensis</i> and <i>Scutellaria Barbata</i> Reveals the Evolution of Active Flavonoid Biosynthesis
Authors: Zhichao Xu, Ranran Gao, Xiangdong Pu, Rong Xu, Jiyong Wang, Sihao Zheng, Yan Zeng, Jun Chen, Chunnian He, Jingyuan Song
Journal: Genomics Proteomics & Bioinformatics (2020)

Scutellaria baicalensis (S. baicalensis) and Scutellaria barbata (S. barbata) are common medicinal plants of the Lamiaceae family. Both produce specific flavonoid compounds, including baicalein, scutellarein, norwogonin, and wogonin, as well as their glycosides, which exhibit antioxidant and antitumor activities. Here, we report chromosome-level genome assemblies of S. baicalensis and S. barbata with quantitative chromosomal variation (2n = 18 and 2n = 26, respectively). The divergence of S. baicalensis and S. barbata occurred far earlier than previously reported, and a whole-genome duplication (WGD) event was identified. The insertion of long terminal repeat elements after speciation might be responsible for the observed chromosomal expansion and rearrangement. Comparative genome analysis of the congeneric species revealed the species-specific evolution of chrysin and apigenin biosynthetic genes, such as the S. baicalensis-specific tandem duplication of genes encoding phenylalanine ammonia lyase and chalcone synthase, and the S. barbata-specific duplication of genes encoding 4-CoA ligase. In addition, the paralogous duplication, colinearity, and expression diversity of CYP82D subfamily members revealed the functional divergence of genes encoding flavone hydroxylase between S. baicalensis and S. barbata. Analyzing these Scutellaria genomes reveals the common and species-specific evolution of flavone biosynthetic genes. Thus, these findings would facilitate the development of molecular breeding and studies of biosynthesis and regulation of bioactive compounds.
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Authors: Michael G. Shlipak, Sri Lekha Tummalapalli, L. Ebony Boulware, Morgan E. Grams, Joachim H. Ix, Vivekanand Jha, Andre-Pascal Kengne, Magdalena Madero, Borislava Mihaylova, Navdeep Tangri, Michael Cheung, Michel Jadoul, Wolfgang C. Winkelmayer, Sophia Zoungas, Georgi Abraham, Zanfina Ademi, Radica Z. Alicic, Ian de Boer, Raj Deo, Xiaoqiang Ding, Natalie Ebert, Kevin J. Fowler, Linda F. Fried, Ron T. Gansevoort, Guillermo Garcia-Garcia, Brenda R. Hemmelgarn, Jessica Lee Harding, Joanna Q. Hudson, Kunitoshi Iseki, Vasantha Jotwani, Leah S. Karliner, Andrew S. Levey, Adrian Liew, Peter J. Lin, Andrea O.Y. Luk, Verónica Martínez, Andrew E. Moran, Mai Nguyen, Gregorio T. Obrador, Donal O’Donoghue, Meda E. Pavkov, Jessie Pavlinac, Neil R. Powe, Jesse C. Seegmiller, Jenny I. Shen, Rukshana Shroff, Laura Solá, Maarten W. Taal, James Tattersall, Joseph A. Vassalotti, Matthew R. Weir, Ella Zomer
Journal: Kidney International (2020)

Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prioritize early identification and intervention for CKD. Guidelines on evaluating and managing early CKD are available but have not been universally adopted in the absence of incentives or quality measures for prioritizing CKD care. The burden of CKD falls disproportionately upon persons with lower socioeconomic status, who have a higher prevalence of CKD, limited access to treatment, and poorer outcomes. Therefore, identifying and treating CKD at the earliest stages is an equity imperative. In 2019, Kidney Disease: Improving Global Outcomes (KDIGO) held a controversies conference entitled "Early Identification and Intervention in CKD." Participants identified strategies for screening, risk stratification, and treatment for early CKD and the key health system and economic factors for implementing these processes. A consensus emerged that CKD screening coupled with risk stratification and treatment should be implemented immediately for high-risk persons and that this should ideally occur in primary or community care settings with tailoring to the local context.
Estimated Prevalence of Masked Asleep Hypertension in US Adults
Authors: Siling Li, Joseph E. Schwartz, Daichi Shimbo, Paul Muntner, James M. Shikany, John N. Booth, Norrina B. Allen, Byron C. Jaeger, Adam P. Bress, Jordan B. King, Donald Clark, Kenneth R. Butler, Adolfo Correa, Andrew E. Moran, Brandon K. Bellows, Yiyi Zhang
Journal: JAMA Cardiology (2020)

High blood pressure (BP) during sleep (asleep blood pressure) is associated with an increased risk of cardiovascular disease, but a national prevalence estimate of masked asleep hypertension (high BP while sleeping but without high BP measured in the clinic [clinic BP]) for the United States is lacking.
TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response
Authors: Susan DeWolf, Katherine Nichols, Chi L. Nguyen, Paul A Giardina, John B. Slingerland, Harold Elias, Rajya Kappangantula, Priscilla Baez, Rajmohan Murali, Akimasa Hayashi, Anqi Dai, Heather J Landau, Roni Tamari, Alan M. Hanash, Robert Jenq, Sergio Giralt, Miguel-Angel Perales, Kate A Markey, Christine Iacobuzio-Donahue, Marcel van den Brink, Jonathan U Peled
Journal: Blood (2020)